Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DPH001
MIFTS: 62

Diphtheria

Categories: Rare diseases, Infectious diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Diphtheria

About this section

MalaCards integrated aliases for Diphtheria:

Name: Diphtheria 12 76 53 59 55 43 3 44 15 73
Corynebacterium Infections 44 73
Diphtheria, Susceptibility to 13
Corynebacterium Infection 12

Characteristics:

Orphanet epidemiological data:

59
diphtheria
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 34 33
Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11405
SNOMED-CT 68 397434007
Orphanet 59 ORPHA1679
ICD10 via Orphanet 34 A36.1 A36.2 A36.3 more
MESH via Orphanet 45 D004165
UMLS via Orphanet 74 C0012546
ICD10 33 A36 A36.9
Sources

Summaries for Diphtheria

About this section
MedlinePlus : 43 Diphtheria is a serious bacterial infection. You can catch it from a person who has the infection and coughs or sneezes. You can also get infected by coming in contact with an object, such as a toy, that has bacteria on it. Diphtheria usually affects the nose and throat. Symptoms include Sore throat Swollen glands in the neck Fever Weakness Your doctor will diagnose it based on your signs and symptoms and a lab test. Getting treatment for diphtheria quickly is important. If your doctor suspects that you have it, you'll start treatment before the lab tests come back. Treatment is with antibiotics. The diphtheria, pertussis, and tetanus vaccine can prevent diphtheria, but its protection does not last forever. Children need another dose, or booster, at about age 12. Then, as adults, they should get a booster every 10 years. Diphtheria is very rare in the United States because of the vaccine. Centers for Disease Control and Prevention

MalaCards based summary : Diphtheria, also known as corynebacterium infections, is related to tetanus and mucositis, and has symptoms including coughing, fever and pruritus. An important gene associated with Diphtheria is HBEGF (Heparin Binding EGF Like Growth Factor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Natalizumab and Edetic Acid have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and skin, and related phenotypes are Increased viability with SS1P at EC90 and growth/size/body region

CDC : 3 Diphtheria is an infection caused by the bacterium Corynebacterium diphtheriae. Diphtheria causes a thick covering in the back of the throat. It can lead to difficulty breathing, heart failure, paralysis, and even death. Vaccines are recommended for infants, children, teens and adults to prevent diphtheria.

Disease Ontology : 12 A primary bacterial infectious disease that is characterized by sore throat, low fever, and an adherent membrane (a pseudomembrane) on the tonsils, pharynx, and/or nasal cavity. A milder form of diphtheria can be restricted to the skin. It is caused by Corynebacterium diphtheriae, an aerobic Gram-positive bacterium. Diphtheria toxin spreads through the bloodstream and can lead to potentially life-threatening complications that affect other organs of the body, such as the heart and kidneys.

Wikipedia : 76 Diphtheria is an infection caused by the bacterium Corynebacterium diphtheriae. Signs and symptoms may... more...

Sources

Related Diseases for Diphtheria

About this section

Diseases related to Diphtheria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Related Disease Score Top Affiliating Genes
1 tetanus 31.0 IL13 IL2 IL2RA
2 mucositis 29.4 CSF2 EGF IL2
3 leukemia, acute myeloid 28.5 CSF2 IL2 IL3 IL3RA PARP1
4 malaria 26.7 CSF2 IL13 IL2 IL2RB PLAUR
5 cutaneous diphtheria 12.5
6 granulomatous lobular mastitis 10.9
7 pseudomembranous conjunctivitis 10.9
8 diphtheritic peritonitis 10.9
9 specific antibody deficiency 10.9
10 pertussis 10.8
11 influenza 10.5
12 primary bacterial infectious disease 10.5 EEF2 HBEGF IL2
13 virus associated hemophagocytic syndrome 10.4 IL2 IL2RB
14 haemophilus influenzae 10.4
15 hepatitis 10.4
16 hepatitis b 10.4
17 aging 10.4
18 rheumatoid factor-negative juvenile idiopathic arthritis 10.4 IL2RA IL2RB
19 poliomyelitis 10.3
20 scarlet fever 10.3
21 measles 10.2
22 leukemia 10.2
23 large granular lymphocyte leukemia 10.2 CSF2 IL2RA
24 b-cell expansion with nfkb and t-cell anergy 10.1 IL2 IL2RA IL2RB
25 capillary disease 10.1 CSF2 IL2
26 myeloid leukemia 10.1
27 pulmonary sarcoidosis 10.0 CSF2 IL2 IL2RA
28 seborrheic infantile dermatitis 10.0 CSF2 IL3
29 visceral leishmaniasis 10.0 EEF2 IL13 IL2
30 mumps 10.0
31 myocarditis 10.0
32 rubella 10.0
33 endocarditis 9.9
34 immune deficiency disease 9.9 IL2 IL2RA IL2RB
35 bladder cancer 9.9
36 glioblastoma 9.9
37 pancreatic cancer 9.8
38 hepatitis a 9.8
39 melanoma 9.8
40 pancreatitis 9.8
41 neuronitis 9.8
42 mastitis 9.8
43 granulomatous mastitis 9.8
44 ovarian cancer 9.8
45 paralytic poliomyelitis 9.8
46 lymphoma 9.8
47 prostatitis 9.8
48 laryngitis 9.8
49 pneumonia 9.8
50 toxic myocarditis 9.8

Comorbidity relations with Diphtheria via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Diphtheria:



Diseases related to Diphtheria
Sources

Symptoms & Phenotypes for Diphtheria

About this section

UMLS symptoms related to Diphtheria:


coughing, fever, pruritus, snoring, tinnitus, sore throat, vertigo/dizziness, equilibration disorder

GenomeRNAi Phenotypes related to Diphtheria according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with SS1P at EC90 GR00376-A-1 9.02 DNAJC24 DPH1 DPH2 DPH3 FURIN

MGI Mouse Phenotypes related to Diphtheria:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.24 PLAUR IL2RB PARP1 CD9 EGF FURIN
2 hematopoietic system MP:0005397 10.1 PLAUR IL2RB IL3RA PARP1 CD9 FURIN
3 immune system MP:0005387 10.03 PARP1 PLAUR IL2RB IL3RA EGF CD9
4 embryo MP:0005380 10.01 PARP1 IL2RB EEF2 FURIN CSF2 DNAJC24
5 mortality/aging MP:0010768 9.77 PARP1 IL2RA IL2RB FURIN CSF2 HBEGF
6 integument MP:0010771 9.76 PARP1 IL2RB EGF FURIN CSF2 HBEGF
7 respiratory system MP:0005388 9.23 PLAUR IL2RA CD9 CSF2 HBEGF DPH1
Sources

Drugs & Therapeutics for Diphtheria

About this section

Drugs for Diphtheria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Natalizumab Approved, Investigational Phase 4 189261-10-7
2
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
3
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
4
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
5
Adalimumab Approved Phase 4 331731-18-1 16219006
6
Etanercept Approved, Investigational Phase 4 185243-69-0
7
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
8
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
9
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
10
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
11
Lopinavir Approved Phase 4 192725-17-0 92727
12
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
13
Lactitol Investigational Phase 4,Phase 3,Phase 2 585-86-4 3871
14
BCG vaccine Investigational Phase 4,Phase 2
15 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Aluminum phosphate Phase 4,Phase 3,Phase 1,Phase 2
23 Antacids Phase 4,Phase 3,Phase 2,Phase 1
24 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Antidotes Phase 4,Phase 3,Phase 2
27 Antitoxins Phase 4,Phase 3
28 Diphtheria Antitoxin Phase 4,Phase 3
29 Tetanus Antitoxin Phase 4,Phase 3
30 Keyhole-limpet hemocyanin Phase 4,Phase 1
31 Anticoagulants Phase 4,Phase 3,Phase 2
32 Calcium, Dietary Phase 4,Phase 3,Phase 2
33 Chelating Agents Phase 4,Phase 3,Phase 2
34 Iron Chelating Agents Phase 4,Phase 3,Phase 2
35 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
36 PENTA Phase 4,Phase 3,Phase 2
37 Antirheumatic Agents Phase 4,Phase 2
38 Interleukin 1 Receptor Antagonist Protein Phase 4
39 MF59 oil emulsion Phase 4,Phase 2
40 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
44 Immunosuppressive Agents Phase 4,Phase 2
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Antipyretics Phase 4,Phase 3
47 Cyclooxygenase Inhibitors Phase 4,Phase 2
48 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2
49 Immunoglobulin G Phase 4
50 Anti-HIV Agents Phase 4,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 561)
# Name Status NCT ID Phase Drugs
1 An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster Unknown status NCT00870350 Phase 4
2 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
3 The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients Unknown status NCT00336115 Phase 4
4 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
5 Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates Unknown status NCT02179996 Phase 4
6 Pertussis (Tdap) Vaccination in Pregnancy Unknown status NCT01698346 Phase 4
7 Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td Completed NCT00601835 Phase 4
8 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine Completed NCT03552445 Phase 4
9 Immunogenicity and Safety of Concomitant Administration of RotaTeqâ„¢ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
10 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
11 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
12 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
13 Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine Completed NCT00347958 Phase 4
14 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
15 Study of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
16 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older Completed NCT00457249 Phase 4
17 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
18 Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine Completed NCT00674908 Phase 4
19 Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekidsâ„¢ Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarixâ„¢ (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
20 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
21 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
22 Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® Completed NCT00319553 Phase 4
23 Regulatory Post-Marketing Surveillance Study for TETRAXIMâ„¢ Completed NCT01437423 Phase 4
24 Maternal Flu Vaccine Trial in Bamako, Mali Completed NCT01430689 Phase 4
25 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
26 Post Marketing Surveillance for ADACELâ„¢ in South Korea Completed NCT01137435 Phase 4
27 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
28 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
29 Tdap Vaccine in Post-Partum Women Completed NCT01711645 Phase 4
30 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACELâ„¢ Completed NCT00802867 Phase 4
31 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Completed NCT00777257 Phase 4
32 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Completed NCT00244673 Phase 4
33 Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine Completed NCT00617812 Phase 4
34 Assessment of the Immunogenicity and Safety of PENTAXIMâ„¢ in Philippines Completed NCT00254917 Phase 4
35 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
36 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. Completed NCT00610168 Phase 4
37 Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
38 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) Completed NCT00289913 Phase 4
39 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
40 Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines Completed NCT01270503 Phase 4
41 Evaluation of Boostrixâ„¢10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4
42 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
43 Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose Completed NCT01823536 Phase 4
44 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination Completed NCT00548171 Phase 4
45 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
46 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrixâ„¢ Vaccine in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo
47 Tropical Influenza Control Strategies for the Elderly Completed NCT02655874 Phase 4
48 Immunogenicity and Safety of TETRAXIMâ„¢ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
49 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis Completed NCT00536120 Phase 4
50 Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) Completed NCT01294605 Phase 4

Search NIH Clinical Center for Diphtheria

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: diphtheria

Sources

Genetic Tests for Diphtheria

About this section
Sources

Anatomical Context for Diphtheria

About this section

MalaCards organs/tissues related to Diphtheria:

41
Heart, Kidney, Skin, Testes, Tonsil, Lymph Node, Eye
Sources

Publications for Diphtheria

About this section

Articles related to Diphtheria:

(show top 50) (show all 954)
# Title Authors Year
1
Seroepidemiology of diphtheria and pertussis in Chongqing, China: serology-based evidence of Bordetella pertussis infection. ( 29408190 )
2018
2
Myocarditis following diphtheria, whole-cell pertussis, and tetanus toxoid vaccination in a young infant. ( 29922028 )
2018
3
A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults. ( 29172945 )
2018
4
Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. ( 29862604 )
2018
5
Vascular Endothelial Growth Factor-A165b Restores Normal Glomerular Water Permeability in a Diphtheria-Toxin Mouse Model of Glomerular Injury. ( 29393270 )
2018
6
Effectiveness of Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination in the Prevention of Infant Pertussis in the U.S. ( 29910115 )
2018
7
The association between tuberculosis and diphtheria. ( 29665871 )
2018
8
Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. ( 29438562 )
2018
9
A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital. ( 29217370 )
2018
10
Pharmacists' Attitudes and Practices Regarding Tetanus, Diphtheria and Pertussis (Tdap) Vaccination in Pregnancy and Surrounding Newborns. ( 29693570 )
2018
11
GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine. ( 29961602 )
2018
12
Carrier study and treatment of close contacts: A must for diphtheria eradication. ( 29735850 )
2018
13
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial. ( 29066131 )
2018
14
Immunogenicity of diphtheria toxoid and poly(I:C) loaded cationic liposomes after hollow microneedle-mediated intradermal injection in mice. ( 29870743 )
2018
15
Optimal route of diphtheria toxin administration to eliminate native nephron progenitor cells inA vivo for kidney regeneration. ( 29408475 )
2018
16
Diphtheria in Children in Northern Haiti. ( 29688558 )
2018
17
NMR study of mutations of glycine-52 of the catalytic domain of diphtheria toxin. ( 29216588 )
2018
18
Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy: ERRATUM. ( 29652740 )
2018
19
Patient attitudes toward influenza and tetanus, diphtheria and acellular pertussis vaccination in pregnancy. ( 29907484 )
2018
20
Development of nanoparticle adjuvants to potentiate the immune response against diphtheria toxoid. ( 29171990 )
2018
21
Treatment of MCPT8<sup>DTR</sup>mice with high- or low-dose diphtheria toxin leads to differential depletion of basophils and granulocyte-macrophage progenitors. ( 29315532 )
2018
22
Cutaneous Diphtheria Mimicking Pyoderma Gangrenosum. ( 29282460 )
2018
23
Diphtheria Outbreak in Amerindian Communities, Wonken, Venezuela, 2016-2017. ( 29912686 )
2018
24
Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis. ( 29231748 )
2018
25
Immunization of preterms with hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: The position of the Italian Pediatric Society. ( 29880242 )
2018
26
Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study. ( 29960800 )
2018
27
Lichen planus following tetanus-diphtheria-acellular pertussis vaccination: A case report and review of the literature. ( 29326823 )
2018
28
Cutaneous Diphtheria. ( 29590546 )
2018
29
Cardiac complications in diphtheria and predictors of outcomes. ( 29287886 )
2018
30
Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). ( 29702631 )
2018
31
Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity. ( 29336924 )
2018
32
The preventable tragedy of diphtheria in the 21st century. ( 29871739 )
2018
33
A single booster dose of diphtheria vaccine is effective for travelers regardless of time interval since previous doses. ( 29931363 )
2018
34
Safety Surveillance of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccines. ( 29866795 )
2018
35
SAFETY AND IMMUNOGENICITY STUDY OF A SINGLE DOSE OF A MENINGOCOCCAL (GROUPS A, C, W, and Y) POLYSACCHARIDE DIPHTHERIA TOXOID CONJUGATE VACCINE (MEN-ACWY-D) IN HEALTHY JAPANESE PARTICIPANTS. ( 29962480 )
2018
36
Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10A years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study. ( 29630439 )
2018
37
Diphtheria, pertussis, and tetanus: evidence-based management of pediatric patients in the emergency department ( 28749121 )
2017
38
Diphtheria vaccine: WHO position paper, August 2017 - Recommendations. ( 28822645 )
2017
39
Combined Poly(Lactide-Co-Glycolide) Microspheres Containing Diphtheria Toxoid for a Single-shot Immunization. ( 29238945 )
2017
40
Augmentation of humoral and cellular immunity in response to Tetanus and Diphtheria toxoids by supercritical carbon dioxide extracts of Hippophae rhamnoides L. leaves. ( 28092864 )
2017
41
Respiratory diphtheria due to Corynebacterium ulcerans transmitted by a companion dog, Italy 2014. ( 28647898 )
2017
42
Committee Opinion No. 718: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination. ( 28832489 )
2017
43
Demand- and supply-side determinants of diphtheria-pertussis-tetanus nonvaccination and dropout in rural India. ( 28081971 )
2017
44
Negative Correlation between Circulating CD4(+)FOXP3(+)CD127(-) Regulatory T Cells and Subsequent Antibody Responses to Infant Measles Vaccine but Not Diphtheria-Tetanus-Pertussis Vaccine Implies a Regulatory Role. ( 28855899 )
2017
45
Characterization of serum anti-diphtheria antibody activity following administration of equine anti-toxin for suspected diphtheria. ( 28933665 )
2017
46
Sex-differential effects of diphtheria-tetanus-pertussis vaccine for the outcome of paediatric admissions? A hospital based observational study from Guinea-Bissau. ( 29107347 )
2017
47
Committee Opinion No. 718 Summary: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination. ( 28832480 )
2017
48
Auditory Neuropathy after Damage to Cochlear Spiral Ganglion Neurons in Mice Resulting from Conditional Expression of Diphtheria Toxin Receptors. ( 28743950 )
2017
49
Cellular Entry of the Diphtheria Toxin Does Not Require the Formation of the Open-Channel State by Its Translocation Domain. ( 28937631 )
2017
50
A new mouse line for cell ablation by diphtheria toxin subunit A controlled by a Cre-dependent FLEx switch. ( 28875587 )
2017
Sources

Variations for Diphtheria

About this section
Sources

Expression for Diphtheria

About this section
Search GEO for disease gene expression data for Diphtheria.
Sources

Pathways for Diphtheria

About this section

Pathways related to Diphtheria according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.98 CSF2 EEF2 EGF HBEGF IL13 IL2
2
ERK Signaling 64
Show member pathways
 13.8 CSF2 EGF HBEGF IL13 IL2 IL2RA
3
Metabolism of proteins 66
Show member pathways
 13.74 DNAJC24 DPH1 DPH2 DPH3 DPH7 EEF2
4
Developmental Biology 66
Show member pathways
 13.45 CSF2 EGF FURIN HBEGF IL2 IL2RA
5
TGF-Beta Pathway 64
Show member pathways
 13.44 EGF IL13 IL2 IL2RA IL2RB IL3
6
Akt Signaling 64
Show member pathways
 13.35 CSF2 EGF IL13 IL2 IL2RA IL2RB
7
Cytokine Signaling in Immune system 66
Show member pathways
 13.3 CSF2 EGF HBEGF IL13 IL2 IL2RA
8
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 13.25 CD9 CSF2 EGF IL2 IL2RA IL2RB
9
PAK Pathway 64
Show member pathways
 13.21 CSF2 EGF HBEGF IL13 IL2 IL2RA
10
p70S6K Signaling 64
Show member pathways
 13 EEF2 EGF HBEGF IL2 IL2RA IL3
11
PI3K-Akt signaling pathway 37
Show member pathways
 12.92 EGF IL2 IL2RA IL2RB IL3 IL3RA
12
Pathways in cancer 37
12.78 EGF IL13 IL2 IL2RA IL2RB IL3
13
Influenza A 37
Show member pathways
 12.72 FURIN IL13 IL2 IL2RA IL2RB
14
NF-kappaB Signaling 4
12.49 IL2 IL2RA IL2RB IL3
15
Th17 cell differentiation 37
Show member pathways
 12.38 IL13 IL2 IL2RA IL2RB
16
HTLV-I infection 37
12.36 CSF2 IL2 IL2RA IL2RB
17
Regulation of IFNA signaling 66
Show member pathways
 12.15 CSF2 EGF IL13 IL2 IL2RA IL2RB
18
Immune response Antigen presentation by MHC class II 22
Show member pathways
 12.08 IL2 IL2RA IL2RB
19
G beta-gamma signalling through PI3Kgamma 66
Show member pathways
 11.98 CSF2 IL2 IL2RA IL2RB IL3 IL3RA
20
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.96 EGF IL13 IL2 IL2RA IL2RB IL3
21
MAPK Pathway 72
Show member pathways
 11.95 IL13 IL2 IL2RA
22
IL12-mediated signaling events 1
Show member pathways
 11.89 IL2 IL2RA IL2RB
23
Immune response IL-2 activation and signaling pathway 22
Show member pathways
 11.88 IL2 IL2RA IL2RB IL3 IL3RA
24
Hematopoietic cell lineage 37
11.82 CD9 CSF2 IL2RA IL3 IL3RA
25
Innate Lymphoid Cell Differentiation Pathways 65
11.77 IL13 IL2 IL2RA IL2RB
26
Uptake and actions of bacterial toxins 66
Show member pathways
 11.76 CD9 EEF2 FURIN HBEGF
27
Glucocorticoid receptor regulatory network 1
11.74 CSF2 IL13 IL2
28
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.73 CSF2 IL2 IL2RA IL3
29
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.7 CSF2 IL2 IL2RA IL2RB IL3 IL3RA
30
Dendritic Cells Developmental Lineage Pathway 65
11.68 CSF2 IL2 IL3RA
31
Jak-Stat Signaling Pathway 67
11.68 EGF IL2 IL2RA IL2RB IL3 IL3RA
32
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.63 IL2 IL2RA IL2RB
33
Lung fibrosis 1
11.6 CSF2 EGF IL13
34
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.58 IL2 IL2RA IL2RB
35
Th2 Differentiation Pathway 65
11.44 IL13 IL2 IL2RA IL2RB
36
Inflammatory Response Pathway 1
11.29 IL2 IL2RA IL2RB
37
IL12 signaling mediated by STAT4 1
11.21 IL13 IL2 IL2RA
38
Gamma carboxylation, hypusine formation and arylsulfatase activation 66
Show member pathways
 11.2 DNAJC24 DPH1 DPH2 DPH3 DPH7 EEF2
39
Cytokines and Inflammatory Response 1
11.15 CSF2 IL13 IL2 IL3
Sources

GO Terms for Diphtheria

About this section

Cellular components related to Diphtheria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.65 CD9 FURIN HBEGF IL2RA PLAUR
2 extracellular region GO:0005576 9.61 CSF2 EEF2 EGF FURIN HBEGF IL13
3 external side of plasma membrane GO:0009897 9.46 CD9 IL13 IL2RA IL2RB
4 extracellular space GO:0005615 9.23 CD9 CSF2 EGF FURIN HBEGF IL13

Biological processes related to Diphtheria according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 CSF2 EGF HBEGF IL2 IL3
2 immune response GO:0006955 9.89 CSF2 IL13 IL2 IL2RA IL3
3 regulation of signaling receptor activity GO:0010469 9.88 CSF2 HBEGF IL13 IL2 IL3
4 cytokine-mediated signaling pathway GO:0019221 9.8 CSF2 IL13 IL2 IL2RA IL2RB IL3
5 peptidyl-tyrosine phosphorylation GO:0018108 9.77 CSF2 EGF HBEGF IL3 IL3RA
6 response to ethanol GO:0045471 9.73 EEF2 IL13 IL2
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 CSF2 IL13 IL2 IL3
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.7 EGF HBEGF IL3
9 regulation of molecular function GO:0065009 9.7 CSF2 HBEGF IL2 IL2RA IL2RB IL3
10 positive regulation of T cell differentiation GO:0045582 9.57 IL2 IL2RA
11 MAPK cascade GO:0000165 9.56 CSF2 EGF HBEGF IL2 IL2RA IL2RB
12 regulation of regulatory T cell differentiation GO:0045589 9.55 IL2 IL2RA
13 negative regulation of ERBB signaling pathway GO:1901185 9.54 EGF HBEGF
14 interleukin-2-mediated signaling pathway GO:0038110 9.5 IL2 IL2RA IL2RB
15 negative regulation of lymphocyte proliferation GO:0050672 9.46 IL2 IL2RA
16 regulation of T cell homeostatic proliferation GO:0046013 9.43 IL2 IL2RA
17 peptidyl-diphthamide biosynthetic process from peptidyl-histidine GO:0017183 9.1 DNAJC24 DPH1 DPH2 DPH3 DPH7 EEF2

Molecular functions related to Diphtheria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.67 CSF2 IL13 IL2 IL3
2 protein tyrosine kinase activity GO:0004713 9.55 CSF2 EGF HBEGF IL3 IL3RA
3 growth factor activity GO:0008083 9.35 CSF2 EGF HBEGF IL2 IL3
4 interleukin-2 binding GO:0019976 9.32 IL2RA IL2RB
5 interleukin-2 receptor activity GO:0004911 9.26 IL2RA IL2RB
6 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.23 CSF2 EGF HBEGF IL2 IL2RA IL2RB
Sources

Sources for Diphtheria

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....